Aerie Pharmaceuticals, Inc.
322 articles about Aerie Pharmaceuticals, Inc.
-
Aerie Pharmaceuticals, Inc. Names Marvin J. Garrett As Vice President, Regulatory Affairs And Quality Assurance
2/25/2014
-
Aerie Pharmaceuticals, Inc. Announces Study Results Supporting Additional Mechanism Of Action For Lead Glaucoma Drug Candidate AR-13324
2/25/2014
-
Aerie Pharmaceuticals, Inc. To Present At The RBC Capital Markets Global Healthcare Conference
2/19/2014
-
Aerie Pharmaceuticals, Inc. Reports Positive Results For Lead Candidate AR-13324 In Normotensive Individuals
1/9/2014
-
Aerie Pharmaceuticals, Inc. Reports Positive Results For Lead Candidate AR-13324 In Normotensive Individuals
1/9/2014
-
Aerie Pharmaceuticals, Inc. Reports Third Quarter 2013 Financial Results And Provides Business And Product Development Update
12/5/2013
-
Aerie Pharmaceuticals, Inc. To Announce Third Quarter 2013 Financial Results And Host Conference Call On Wednesday, December 4, 2013
11/20/2013
-
Aerie Pharmaceuticals, Inc. to Ring the NASDAQ Stock Market Closing Bell in Celebration of IPO
10/25/2013
-
Aerie Pharmaceuticals, Inc. Reels in $67 Million in IPO
10/25/2013
-
Aerie Pharmaceuticals, Inc. Eyes $58 Million IPO
9/18/2013
-
Aerie Pharmaceuticals, Inc. Elects Dr. Gerald D. Cagle to the Company’s Board of Directors
9/6/2013
-
Aerie Pharmaceuticals, Inc. Elects Murray Goldberg to the Company’s Board of Directors
8/20/2013
-
Aerie Pharmaceuticals, Inc. Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer
7/26/2013
-
Aerie Pharmaceuticals, Inc. Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board
4/4/2013
-
Aerie Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference
1/3/2013
-
Aerie Pharmaceuticals, Inc. Looks to Raise $15 Million
12/20/2012
-
BioLight Life Sciences Investments Ltd and Aerie Pharmaceuticals, Inc. Affiliates Announce a Collaboration for Continued Development of a Controlled-Release Ocular Implant for the Delivery of Ophthalmic Medications
11/7/2012
-
Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment
11/2/2012
-
Aerie Pharmaceuticals, Inc. Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, With Travoprost for the Treatment of Glaucoma
11/1/2012
-
Aerie Pharmaceuticals, Inc. Appoints Richard J. Rubino as Chief Financial Officer
10/18/2012